These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

770 related articles for article (PubMed ID: 14513166)

  • 41. Difference in response to botulinum toxin type A treatment between patients with benign essential blepharospasm and hemifacial spasm.
    Cannon PS; MacKenzie KR; Cook AE; Leatherbarrow B
    Clin Exp Ophthalmol; 2010 Oct; 38(7):688-91. PubMed ID: 20456439
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Botulinum toxin in blepharospasm and oromandibular dystonia: comparing different botulinum toxin preparations.
    Bhidayasiri R; Cardoso F; Truong DD
    Eur J Neurol; 2006 Feb; 13 Suppl 1():21-9. PubMed ID: 16417594
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Secondary non-response due to antibody formation in a child after three injections of botulinum toxin B into the salivary glands.
    Berweck S; Schroeder AS; Lee SH; Bigalke H; Heinen F
    Dev Med Child Neurol; 2007 Jan; 49(1):62-4. PubMed ID: 17209979
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Management of oromandibular dystonia with botulinum A toxin: a series of cases.
    Teemul TA; Patel R; Kanatas A; Carter LM
    Br J Oral Maxillofac Surg; 2016 Dec; 54(10):1080-1084. PubMed ID: 27776922
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term botulinum toxin treatment of benign essential blepharospasm, hemifacial spasm, and Meige syndrome.
    Czyz CN; Burns JA; Petrie TP; Watkins JR; Cahill KV; Foster JA
    Am J Ophthalmol; 2013 Jul; 156(1):173-177.e2. PubMed ID: 23541393
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Management of refractory idiopathic overactive bladder: intradetrusor injection of botulinum toxin type A versus posterior tibial nerve stimulation.
    Sherif H; Khalil M; Omar R
    Can J Urol; 2017 Jun; 24(3):8838-8846. PubMed ID: 28646940
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Botulinum toxin therapy for focal dystonia].
    Hahn K; Niklai E; Garzuly F; Szupera Z
    Orv Hetil; 2009 Jul; 150(29):1381-4. PubMed ID: 19581172
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Botulinum toxin treatment of hip adductor spasticity in multiple sclerosis].
    Wissel J; Entner T
    Wien Klin Wochenschr; 2001; 113 Suppl 4():20-4. PubMed ID: 15506048
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term follow-up of cervical dystonia patients treated with botulinum toxin A.
    Haussermann P; Marczoch S; Klinger C; Landgrebe M; Conrad B; Ceballos-Baumann A
    Mov Disord; 2004 Mar; 19(3):303-8. PubMed ID: 15022184
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Low-dose botulinum toxin-a treatment of cervical dystonia - a double-blind, randomized pilot study.
    Laubis-Herrmann U; Fries K; Topka H
    Eur Neurol; 2002; 47(4):214-21. PubMed ID: 12037435
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia Study Group.
    Kessler KR; Skutta M; Benecke R
    J Neurol; 1999 Apr; 246(4):265-74. PubMed ID: 10367694
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A randomized, double-masked, crossover comparison of the efficacy and safety of botulinum toxin type A produced from the original bulk toxin source and current bulk toxin source for the treatment of cervical dystonia.
    Naumann M; Yakovleff A; Durif F;
    J Neurol; 2002 Jan; 249(1):57-63. PubMed ID: 11954869
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term botulinum toxin treatment of focal hand dystonia.
    Karp BI; Cole RA; Cohen LG; Grill S; Lou JS; Hallett M
    Neurology; 1994 Jan; 44(1):70-6. PubMed ID: 8290095
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Botulinum toxin B: a review of its therapeutic potential in the management of cervical dystonia.
    Figgitt DP; Noble S
    Drugs; 2002; 62(4):705-22. PubMed ID: 11893235
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety and efficacy of botulinum toxin therapy in otorhinolaryngology: experience from 1,000 treatments.
    Helmstaedter V; Wittekindt C; Huttenbrink KB; Guntinas-Lichius O
    Laryngoscope; 2008 May; 118(5):790-6. PubMed ID: 18300708
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and safety of a standardised 500 unit dose of Dysport (clostridium botulinum toxin type A haemaglutinin complex) in a heterogeneous cervical dystonia population: results of a prospective, multicentre, randomised, double-blind, placebo-controlled, parallel group study.
    Wissel J; Kanovsky P; Ruzicka E; Bares M; Hortova H; Streitova H; Jech R; Roth J; Brenneis C; Müller J; Schnider P; Auff E; Richardson A; Poewe W
    J Neurol; 2001 Dec; 248(12):1073-8. PubMed ID: 12013585
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Botulinum toxin a in the treatment of blepharospasm: a 10-year experience.
    Silveira-Moriyama L; Gonçalves LR; Chien HF; Barbosa ER
    Arq Neuropsiquiatr; 2005 Jun; 63(2A):221-4. PubMed ID: 16100966
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Botulinum toxin F in the treatment of torticollis clinically resistant to botulinum toxin A.
    Sheean GL; Lees AJ
    J Neurol Neurosurg Psychiatry; 1995 Dec; 59(6):601-7. PubMed ID: 7500097
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia.
    Chapman MA; Barron R; Tanis DC; Gill CE; Charles PD
    Clin Ther; 2007 Jul; 29(7):1325-37. PubMed ID: 17825685
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Botulinum toxin injections for the treatment of hemifacial spasm over 16 years.
    Sorgun MH; Yilmaz R; Akin YA; Mercan FN; Akbostanci MC
    J Clin Neurosci; 2015 Aug; 22(8):1319-25. PubMed ID: 26100157
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.